SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that data from preclinical studies showing potential for Cytori’s DCCT-10 cell therapy product in the treatment of hypertrophic scarring (HTS), a common consequence of burn injury, will be presented at the Annual Meeting of the American Burn Association (ABA) in Las Vegas on May 5, 2016.
